Brief: Molecular Templates, Inc. Announces Dosing Of First Subject In Phase 1 Study Of MT-6402 In Pd-L1-Positive Solid Tumors
09/07/2021 13:27
July 9 (Reuters) - Molecular Templates Inc MTEM.O :
* MOLECULAR TEMPLATES, INC. ANNOUNCES DOSING OF FIRST
SUBJECT IN
PHASE 1 STUDY OF MT-6402 IN PD-L1-POSITIVE SOLID TUMORS
Source text for Eikon: ID:nGNX63qSpR
Further company coverage: MTEM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Molecular Templates
See all newsBrief: Molecular Templates Co & Affiliate Commenced Chapter 11 Cases As DIP
Brief: Molecular Templates's Eric E. Poma Resigns As CEO, CSO, Treasurer, And Interim CFO
Brief: Molecular Templates Announces Notice Of Delisting And Failure To Satisfy Continued Listing Rules
Brief: Molecular Templates Announces Receipt Of Expected Notification Of Deficiency From Nasdaq
Brief: Molecular Templates Approved Liquidation & Wind Up Through A Dissolution